Alnylam Pharmaceuticals (LTS:0HD2) ROCE %: 31.97% (As of Mar. 2026)


LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
67 GF Score
Price $291.98
GF Value $511.65
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals ROCE %?

Alnylam Pharmaceuticals LTS:0HD2 -2.26% 67 ROCE % is 31.97% as of Mar. 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $511.65 (Significantly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alnylam Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 31.97%.

Alnylam Pharmaceuticals  (LTS:0HD2) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alnylam Pharmaceuticals ROCE % Related Terms

Alnylam Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals ROCE % Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.58 -33.92 -11.07 -7.96 17.57

Alnylam Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.23 0.61 34.55 34.19 31.97
LTS:0HD2
67GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals ROCE % Calculation

Alnylam Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=575.779/( ( (4239.983 - 1186.272) + (4966.331 - 1466.349) )/ 2 )
=575.779/( (3053.711+3499.982)/ 2 )
=575.779/3276.8465
=17.57 %

Alnylam Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1163.756/( ( (4966.331 - 1466.349) + (5129.547 - 1349.475) )/ 2 )
=1163.756/( ( 3499.982 + 3780.072 )/ 2 )
=1163.756/3640.027
=31.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 31.97% mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a ROCE % of 31.97% as of Mar. 2026.
Is Alnylam Pharmaceuticals' ROCE % too high?
Alnylam Pharmaceuticals' current ROCE % is 31.97%. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' ROCE % compare to RVMD and ONC?
Alnylam Pharmaceuticals' ROCE % of 31.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Alnylam Pharmaceuticals's current ROCE % is 31.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $511.65, compared to a current price of $291.98 — trading 42.9% below its estimated fair value. The current ROCE % is 31.97%. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current ROCE % is 31.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $291.98 is trading 42.9% below its estimated GF Value™ of $511.65. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • ROCE %: 31.97%
  • GF Value™: $511.65 vs. price of $291.98 (42.9% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score

Get the complete analysis for LTS:0HD2

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$291.98
Price
$511.65
GF Value